AS AT SEPTEMBER 30, 2023 TABLE OF CONTENTS Page | Condensed consolidated interim statements of financial position | 1 | | --- | --- | | Condensed consolidated interim statements of profit or loss and other comprehensive income | 2 | | Condensed consolidated interim statements of changes in equity | 3-5 | | Condensed consolidated interim statements of cash flows | 6-7 | | Notes to the condensed consolidated interim financial statements | 8-15 | | - - - - - - - - - - - | | i KAMADA LTD. CONDENSED CONSOLIDATED ...

Exhibit 99.3 AS OF JUNE 30, 2023 TABLE OF CONTENTS | Consolidated Statements of Financial Position | 1 | | --- | --- | | Consolidated Statements of Profit or Loss and Other Comprehensive Income | 2 | | Consolidated Statements of Changes in Equity | 3-5 | | Consolidated Statements of Cash Flows | 6-7 | | Notes to the Interim Consolidated Financial Statements | 8-14 | | - - - - - - - - - - - | | Page i KAMADA LTD. CONSOLIDATED STATEMENTS OF FINANCIAL POSITION | | | | | | | As of | | --- | --- | --- | --- | -- ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2023 was $30.7 million, a 9% increase from $28.1 million in Q1 2022 [6][18] - EBITDA for Q1 2023 was $3.8 million, representing a 16% increase compared to $3.3 million in Q1 2022 [6][44] - Gross profit for Q1 2023 was $11.8 million, with a margin of 39%, compared to $11.3 million and a margin of 40% in Q1 2022 [41] - Net loss for Q1 2023 was approximately $1.8 million, consistent with the prior-year period [56] Business Line Data and Key Metrics Changes - Strong sales of KEDRAB contributed significantly to revenue growth, with the product gaining market share in the US [12][18] - CYTOGAM, which generated approximately $23 million in sales in 2022, has received FDA approval for manufacturing at Kamada's facility [10] - The company anticipates continued growth from its immune globulin product portfolio and distribution business in Israel [18][30] Market Data and Key Metrics Changes - The US market for KEDRAB is estimated to be over $150 million annually, with Kamada's product being the only human rabies immune globulin clinically studied in children [12] - The market for inhaled alpha-1 antitrypsin therapy is over $1 billion in annual sales in the US and Europe, presenting a substantial opportunity for Kamada [16] Company Strategy and Development Direction - The company aims for annual double-digit revenue and profitability growth in the foreseeable future, supported by a $60 million strategic private placement with FIMI Opportunity Funds [5][8] - Kamada is focused on becoming a fully integrated specialty plasma product company, with plans to expand plasma collection capacity in the US [14][37] - The company is exploring opportunities for in-licensing and acquisitions to accelerate growth [50] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, reiterating full-year 2023 revenue guidance of $138 million to $146 million and EBITDA guidance of $22 million to $26 million [22][30] - The company is optimistic about the impact of recent FDA approvals and ongoing clinical trials on future revenue [10][15] Other Important Information - The company incurred a $0.6 million expense for exit severance compensation due to workforce downsizing at its Israeli plant, expected to reduce overall labor costs by approximately 6% [55] - Cash used in operating activities was $2.9 million in Q1 2023, compared to cash provided by operating activities of $5.5 million in Q1 2022 [57] Q&A Session Summary Question: Were there any surprises during the quarter? - Management indicated that the quarter played out as planned, with no significant surprises [58] Question: What is the growth outlook for the year? - Management expects growth to come from KEDRAB, the new IgG portfolio, and distribution business in Israel, reiterating annual guidance [24] Question: Can you provide more details on FIMI? - FIMI is a private equity firm with a strong track record, having invested significantly in Kamada since 2019 [63]

Financial Data and Key Metrics Changes - Total revenue for 2022 was approximately $129 million, representing a 25% increase from $104 million in 2021 [33][8] - EBITDA for 2022 was approximately $18 million, with a margin of 14%, a significant increase from $5.4 million and 5% margin in 2021 [53][9] - Operating cash flow reached a record $28.6 million in 2022, increasing the cash position to $34 million as of December 31, 2022, nearly double from $18.6 million at the end of 2021 [9][54] Business Line Data and Key Metrics Changes - Revenue from acquired products increased by 24% in 2022, generating gross margins over 50% [15][8] - KEDRAB, the rabies immunoglobulin, gained significant market share in the US, contributing to the overall revenue growth [19][20] - GLASSIA royalty income from Takeda was $12.2 million for 2022, with expectations of $10 million to $20 million annually through 2040 [27] Market Data and Key Metrics Changes - The US market for KEDRAB is estimated at $150 million annually, with expectations for continued growth [19] - The company is expanding its international distribution network, particularly in Latin America and the Middle East, with significant contracts secured [24][25] Company Strategy and Development Direction - The company has transitioned from dependence on GLASSIA sales to a diversified specialty plasma company with a global footprint in over 30 countries [7] - Plans to manufacture CYTOGAM at its facility in Israel are underway, with FDA approval expected by mid-2023 [18] - The company aims to leverage its strong international distribution network to grow product revenues in new territories [24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued revenue growth and profitability for 2023, with guidance of $138 million to $146 million in revenue and EBITDA of $22 million to $26 million [10][38] - The company anticipates annual double-digit growth in revenues and profitability in the foreseeable future [47] Other Important Information - Research and development investments increased to $13.2 million in 2022, primarily due to the ongoing Phase 3 InnovAATe trial [51] - The company expects overall expenses, including R&D and marketing, to increase by 15% to 20% in 2023 compared to 2022 [66] Q&A Session Summary Question: Will the company remain cash flow positive? - Management confirmed that the company expects to remain cash-positive and profitable, with strong cash flow generation correlated with EBITDA [40] Question: What are the biggest drivers behind the growth of the acquired products? - Growth was attributed to strong sales in the US and Canada, including significant contracts for VARIZIG and ongoing marketing efforts [57] Question: Is the company working on additional supply contracts? - Management stated that they are actively pursuing additional marketing and registration opportunities for their portfolio in new territories [59] Question: What are the expectations for gross margins in the future? - Management indicated that gross margins are expected to improve as the product mix transitions to more profitable products [60] Question: What is the opportunity with plasma collection centers? - Each mature plasma collection center is expected to contribute approximately $10 million to the top line annually, with plans for additional centers underway [80]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report: Not applicable For the transition period from ____ to _____ Commission file number 001-35948 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ...

[Kamada 2022 Financial Results and 2023 Outlook](index=1&type=section&id=Kamada%202022%20Financial%20Results%20and%202023%20Outlook) [Executive Summary & Key Highlights](index=1&type=section&id=Executive%20Summary%20%26%20Key%20Highlights) The company reported strong 2022 results with 25% revenue growth and a threefold EBITDA increase driven by its acquired IgG portfolio Fiscal Year 2022 Key Financial Metrics | Metric | FY 2022 | FY 2021 | Change | | :--- | :--- | :--- | :--- | | Total Revenues | $129.3 M | $103.6 M | +25% | | EBITDA | $17.8 M | $5.4 M | +229% (3x) | | Operating Cash Flow | $28.6 M | ($8.8 M) | N/A | | Year-End Cash Position | $34.3 M | $18.6 M | +84% | Fiscal Year 2023 Guidance | Metric | 2023 Guidance Range | Mid-point YoY Growth | | :--- | :--- | :--- | | Total Revenues | $138 M - $146 M | +9.8% | | EBITDA | $22 M - $26 M | +35% | - Key growth drivers included the **acquired portfolio of four FDA-approved IgG products**, sales of **KEDRAB** in the U.S, royalties from **GLASSIA**, and a thriving Israeli distribution business[3](index=3&type=chunk)[5](index=5&type=chunk) - The company is advancing its pivotal Phase 3 clinical trial (**InnovAATe**) for Inhaled AAT, with accelerated recruitment and plans to meet with regulatory agencies[5](index=5&type=chunk)[16](index=16&type=chunk) [Detailed Financial Performance](index=2&type=section&id=Detailed%20Financial%20Performance) The company's financials show significant year-over-year improvement in revenue and gross margin for fiscal year 2022 [Fiscal Year 2022 Financial Results](index=2&type=section&id=Fiscal%20Year%202022%20Financial%20Results) Full-year 2022 revenue grew 25% with improved gross margins, though net results were impacted by acquisition-related expenses FY 2022 vs. FY 2021 Performance | Metric | FY 2022 | FY 2021 | | :--- | :--- | :--- | | Total Revenues | $129.3 M | $103.6 M | | Gross Profit | $46.7 M | $30.3 M | | Gross Margin | 36% | 29% | | Operating Expenses | $42.2 M | $31.0 M | | Net Loss | ($2.3 M) | ($2.2 M) | | Adjusted EBITDA | $17.8 M | $5.4 M | - The increase in revenues was primarily attributable to sales of the four acquired IgG products[8](index=8&type=chunk) - Operating expenses rose due to increased Sales & Marketing costs for the acquired portfolio and higher R&D costs for the pivotal Phase 3 InnovAATe trial[8](index=8&type=chunk) - The reported net loss was significantly impacted by a **$6.3 million finance expense** associated with the revaluation of contingent consideration from the IgG products acquisition[8](index=8&type=chunk) [Fourth Quarter 2022 Financial Results](index=3&type=section&id=Fourth%20Quarter%202022%20Financial%20Results) Q4 2022 revenues increased 44% year-over-year, driving a significant gross margin improvement and a return to net income Q4 2022 vs. Q4 2021 Performance | Metric | Q4 2022 | Q4 2021 | | :--- | :--- | :--- | | Total Revenues | $45.4 M | $31.5 M | | Gross Profit | $15.3 M | $6.6 M | | Gross Margin | 34% | 21% | | Net Income (Loss) | $2.9 M | ($5.0 M) | | Adjusted EBITDA | $7.2 M | ($1.3 M) | - The increase in profitability was driven by a positive product sales mix, including sales of the four new IgG products, KEDRAB U.S sales and GLASSIA royalties[11](index=11&type=chunk) [Balance Sheet and Cash Flow](index=2&type=section&id=Balance%20Sheet%20and%20Cash%20Flow) The company nearly doubled its year-end cash position, driven by a record annual operating cash flow of $28.6 million Cash Position and Operating Cash Flow (Year-End) | Metric | 2022 | 2021 | | :--- | :--- | :--- | | Cash, Cash Equivalents, and Short-Term Investments | $34.3 M | $18.6 M | | Cash Provided by (Used in) Operating Activities | $28.6 M | ($8.8 M) | - The increase in the cash position was driven by **continued positive operational cash flows**, indicating significant momentum in commercial operations[12](index=12&type=chunk) [Business Outlook and Corporate Updates](index=4&type=section&id=Business%20Outlook%20and%20Corporate%20Updates) Kamada issued strong 2023 guidance and reported progress on key regulatory submissions and clinical trials Fiscal Year 2023 Guidance | Metric | 2023 Guidance Range | | :--- | :--- | | Total Revenues | $138 million to $146 million | | EBITDA | $22 million to $26 million | - The company has submitted applications to the U.S. FDA and Health Canada to manufacture **CYTOGAM®** at its facility in Beit Kama, Israel[16](index=16&type=chunk) - Progress in the pivotal **Phase 3 InnovAATe trial** for inhaled AAT includes accelerated recruitment and plans to meet with regulatory agencies to discuss the program[16](index=16&type=chunk) [Consolidated Financial Statements](index=7&type=section&id=Consolidated%20Financial%20Statements) This section provides the detailed audited financial statements for the year ended December 31, 2022 [Consolidated Statements of Financial Position](index=7&type=section&id=Consolidated%20Statements%20of%20Financial%20Position) Total assets were $322.4 million as of year-end 2022, reflecting a significant increase in cash and stable equity Balance Sheet Summary (in thousands USD) | Account | Dec 31, 2022 | Dec 31, 2021 | | :--- | :--- | :--- | | Total Current Assets | $139,005 | $130,044 | | Total Non-Current Assets | $183,374 | $188,623 | | **Total Assets** | **$322,379** | **$318,667** | | Total Current Liabilities | $75,705 | $54,057 | | Total Non-Current Liabilities | $70,654 | $87,786 | | **Total Shareholder's Equity** | **$176,020** | **$176,824** | | **Total Liabilities and Equity** | **$322,379** | **$318,667** | [Consolidated Statements of Profit or Loss](index=8&type=section&id=Consolidated%20Statements%20of%20Profit%20or%20Loss) The company reported total revenues of $129.3 million and a net loss of $2.3 million for the full year 2022 Income Statement Summary - Full Year (in thousands USD) | Account | FY 2022 | FY 2021 | | :--- | :--- | :--- | | Total Revenues | $129,339 | $103,642 | | Gross Profit | $46,703 | $30,328 | | Operating Income (Loss) | $4,532 | ($696) | | **Net Income (Loss)** | **($2,321)** | **($2,230)** | | Basic Net Earnings Per Share | ($0.05) | ($0.05) | [Consolidated Statements of Cash Flows](index=9&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) The company generated $28.6 million in cash from operating activities, a strong reversal from the prior year's cash use Cash Flow Summary - Full Year (in thousands USD) | Activity | FY 2022 | FY 2021 | | :--- | :--- | :--- | | Net Cash from Operating Activities | $28,586 | ($8,819) | | Net Cash from Investing Activities | ($3,784) | ($61,050) | | Net Cash from Financing Activities | ($9,343) | $18,593 | | **Increase (Decrease) in Cash** | **$15,671** | **($51,610)** | | **Cash at End of Period** | **$34,258** | **$18,587** | [Non-IFRS Measures Reconciliation](index=11&type=section&id=Non-IFRS%20Measures%20Reconciliation) A reconciliation from IFRS net loss to non-IFRS Adjusted EBITDA resulted in $17.8 million for fiscal year 2022 Reconciliation to Adjusted EBITDA - Full Year (in thousands USD) | Line Item | FY 2022 | FY 2021 | | :--- | :--- | :--- | | Net Income (Loss) | ($2,321) | ($2,230) | | Taxes on income | $62 | $345 | | Financial expense (income), net | $6,791 | $1,189 | | Depreciation and amortization | $12,155 | $5,609 | | Non-cash share-based compensation | $1,153 | $529 | | **Adjusted EBITDA** | **$17,840** | **$5,442** |

Financial Data and Key Metrics Changes - Total revenues for Q3 2022 were $32.2 million, a 40% increase year-over-year, with gross margins rising to 40% from 25% in Q3 2021 [10][34] - Adjusted EBITDA for Q3 2022 was $6 million, representing a 19% margin, while for the first nine months of 2022, adjusted EBITDA was $10.6 million, a 58% increase compared to the previous year [10][41] - The company generated positive cash flow from operating activities for the third consecutive quarter, resulting in a cash position of $31.3 million as of September 30, 2022 [11][43] Business Line Data and Key Metrics Changes - The growth in revenues was primarily driven by strong sales of the recently acquired IgG products, including CYTOGAM, HEPAGAM, VARIZIG, and WINRHOSDF [8][34] - KEDRAB sales also grew significantly during Q3 2022, contributing to the overall revenue increase [21][36] - Royalty income from GLASSIA sales to Takeda amounted to $3.5 million in Q3 2022, representing pure profit for the company [22][36] Market Data and Key Metrics Changes - The U.S. market is seeing a positive trend in KEDRAB sales, which is expected to continue as the product gains market share in a $150 million market [21] - Internationally, a significant $11.4 million agreement to supply VARIZIG was signed, with anticipated revenues expected in Q4 2022 [17][18] - The company is also expanding its presence in the U.S. market with a dedicated sales team promoting its portfolio of specialty plasma-derived immunoglobulins [14][16] Company Strategy and Development Direction - The company is focused on achieving double-digit growth rates in the foreseeable future, driven by its proprietary product categories [31][58] - Kamada is actively pursuing additional commercial contracts in strategic territories and has established a direct presence in the U.S. market [19][24] - The company plans to expand its plasma collection capabilities in the U.S. to enhance its competitive position [25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving continued revenue growth and enhanced profitability in Q4 2022, reiterating full-year revenue guidance of $125 million to $135 million [12][58] - The management highlighted the successful strategic transition of the company and the positive feedback from U.S. physicians regarding the product portfolio [8][16] - Future catalysts include the ongoing Phase 3 InnovAATe clinical trial and the anticipated FDA approval for CYTOGAM production [26][20] Other Important Information - Research and development investments increased to $10.2 million in the first nine months of 2022, primarily due to the InnovAATe trial expansion [39] - Selling and marketing expenses rose due to the establishment of U.S. commercial operations and pre-commercial activities for new product launches [39] Q&A Session Summary Question: How will the company achieve its full-year revenue guidance? - Management indicated that the fourth quarter will benefit from the VARIZIG supply agreement, significant pending orders in the Israel Distribution segment, and continued growth of the new IgG portfolio products [46][47] Question: Should increased operating expenses be expected in 2023? - Management confirmed that 2023 will see a full year of U.S. sales and marketing activities, with expected operational expenses increasing by approximately 10% to 12% compared to 2022 [48][49] Question: Will sales growth from acquired products come from international contracts or U.S. market activities? - Management stated that both aspects are contributing to growth, with ongoing sales activities in the U.S. and international contracts already yielding results [50][52] Question: What is the coverage strategy for transplant centers? - The company is focusing on larger transplant centers and those that have not used its products recently, aiming to cover 150 to 200 centers with a dedicated team [53][54] Question: Is there an ongoing effort to expand the product portfolio? - Management confirmed that the company is building the right infrastructure to look for synergistic products, with efforts continuing through 2023 [55]

Kamada Ltd. (NASDAQ:KMDA) Q2 2022 Earnings Conference Call August 17, 2022 8:30 AM ET Company Representatives Amir London - Chief Executive Officer Chaime Orlev - Chief Financial Officer Bob Yedid - LifeSci Advisors Conference Call Participants Anthony Petrone - Mizuho Group Operator Greetings, and welcome to the Kamada Ltd., Second Quarter 2022 Earnings Call. At this time all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions]. ...

Consolidated Financial Statements [Consolidated Statements of Financial Position](index=2&type=section&id=Consolidated%20Statements%20of%20Financial%20Position) Kamada Ltd. reported total assets of **$304.1 million** as of June 30, 2022, a decrease from **$318.7 million** at year-end 2021, with liabilities at **$132.6 million** and equity at **$171.6 million** | Financial Item | June 30, 2022 (Unaudited, in thousands) | Dec 31, 2021 (Audited, in thousands) | Change (in thousands) | | :--- | :--- | :--- | :--- | | **Total Current Assets** | $118,601 | $130,044 | -$11,443 | | **Total Non-Current Assets** | $185,534 | $188,623 | -$3,089 | | **Total Assets** | **$304,135** | **$318,667** | **-$14,532** | | **Total Current Liabilities** | $49,680 | $54,057 | -$4,377 | | **Total Non-Current Liabilities** | $82,881 | $87,786 | -$4,905 | | **Total Liabilities** | **$132,561** | **$141,843** | **-$9,282** | | **Total Shareholder's Equity** | **$171,574** | **$176,824** | **-$5,250** | [Consolidated Statements of Profit or Loss and Other Comprehensive Income](index=3&type=section&id=Consolidated%20Statements%20of%20Profit%20or%20Loss%20and%20Other%20Comprehensive%20Income) For the six months ended June 30, 2022, revenues rose to **$51.7 million**, but increased operating expenses resulted in an operating loss of **$2.0 million** and a net loss of **$5.7 million** | Metric (Six months ended June 30) | 2022 (Unaudited, in thousands) | 2021 (Unaudited, in thousands) | Change | | :--- | :--- | :--- | :--- | | **Total Revenues** | $51,683 | $49,139 | +5.2% | | **Gross Profit** | $18,542 | $18,003 | +3.0% | | **Operating Income (Loss)** | ($2,048) | $3,410 | -160.1% | | **Net Income (Loss)** | ($5,749) | $3,624 | -258.6% | | **Basic Net Earnings Per Share** | ($0.13) | $0.08 | -262.5% | [Consolidated Statements of Changes in Equity](index=4&type=section&id=Consolidated%20Statements%20of%20Changes%20in%20Equity) Total shareholder's equity decreased by **$5.3 million** during the first six months of 2022, from **$176.8 million** to **$171.6 million**, primarily due to a **$5.7 million** net loss | Equity Component (Six months ended June 30, 2022) | Amount (in thousands) | | :--- | :--- | | **Balance as of January 1, 2022** | **$176,824** | | Net Loss | ($5,749) | | Other Comprehensive Loss | ($76) | | Exercise of share-based payment | $6 | | Cost of share-based payment | $569 | | **Balance as of June 30, 2022** | **$171,574** | [Consolidated Statements of Cash Flows](index=7&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) For the six months ended June 30, 2022, operating activities generated **$16.4 million** in cash, a significant improvement, resulting in an overall **$11.3 million** increase in cash and cash equivalents | Cash Flow Activity (Six months ended June 30) | 2022 (Unaudited, in thousands) | 2021 (Unaudited, in thousands) | | :--- | :--- | :--- | | **Net cash provided by (used in) operating activities** | $16,352 | ($1,178) | | **Net cash provided by (used in) investing activities** | ($1,191) | $100 | | **Net cash provided by (used in) financing activities** | ($4,211) | ($791) | | **Increase (decrease) in cash and cash equivalents** | $11,346 | ($1,781) | | **Cash and cash equivalents at end of period** | $29,933 | $68,416 | [Notes to the Interim Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20the%20Interim%20Consolidated%20Financial%20Statements) This section provides detailed context for the financial statements, outlining business activities, accounting policies, key events, segment performance, financial instruments, and subsequent events [Note 1: General](index=12&type=section&id=Note%201%3A%20General) Kamada is a global biopharmaceutical company focused on plasma-derived therapeutics, strategically expanding its U.S. commercial presence and transitioning its GLASSIA agreement with Takeda to a royalty model - The company's strategy focuses on profitable growth from its commercial portfolio of specialty plasma-derived therapeutics and its manufacturing and development expertise[15](index=15&type=chunk) - In November 2021, Kamada acquired a portfolio of four FDA-approved plasma-derived products from Saol Therapeutics to strengthen its U.S. commercial capabilities[16](index=16&type=chunk) - Effective 2022, the company's agreement with Takeda for GLASSIA transitioned to a royalty-based model. Kamada will receive a **12% royalty** on net sales through August 2025, and **6% thereafter until 2040**, with a minimum of **$5 million annually**[17](index=17&type=chunk) [Note 2: Significant Accounting Policies](index=13&type=section&id=Note%202%3A%20Significant%20Accounting%20Policies) Interim consolidated financial statements are prepared under IAS 34, noting upcoming IAS 1 and IAS 12 amendments effective January 1, 2023, with impacts largely unassessed or not expected to affect statements - The financial statements have been prepared in accordance with **IAS 34** for interim periods[19](index=19&type=chunk) - An amendment to **IAS 1** regarding the classification of liabilities as current or non-current is effective January 1, 2023, but the company believes it will not have an effect on its financial statements[20](index=20&type=chunk)[21](index=21&type=chunk)[22](index=22&type=chunk) - An amendment to **IAS 12** regarding deferred tax on assets and liabilities from a single transaction is effective January 1, 2023. The company has not yet commenced examining its effects[22](index=22&type=chunk)[24](index=24&type=chunk) [Note 3: Significant events in the reporting period](index=14&type=section&id=Note%203%3A%20Significant%20events%20in%20the%20reporting%20period) Key events include a significant stock option grant, a labor strike at Beit Kama resulting in a **$3.34 million** loss, and a **$420 thousand** reduction in employee benefit liability due to bond yield increases - On February 28, 2022, the Board approved the grant of options to purchase up to **1,345,600 shares** for employees/officers, **400,000** for the CEO, and **270,000** for Board members[25](index=25&type=chunk) - A labor strike at the Beit Kama production facility, which began on April 26, 2022, resulted in a loss of **$3.34 million** during the second quarter, recorded in the cost of revenues from proprietary products[28](index=28&type=chunk)[29](index=29&type=chunk) - An increase in the yield of high-quality corporate bonds led to a change in the discount rate, reducing the employee benefit liability by **$420 thousand**, which was recognized in other comprehensive income[29](index=29&type=chunk)[30](index=30&type=chunk) [Note 4: Operating Segments](index=15&type=section&id=Note%204%3A%20Operating%20Segments) The company operates in Proprietary Products and Distribution segments, with Proprietary Products generating **$41.6 million** revenue and **$16.9 million** gross profit, and the U.S.A. and North America as the largest market | Segment (Six months ended June 30, 2022) | Revenues (in thousands) | Gross Profit (in thousands) | | :--- | :--- | :--- | | **Proprietary Products** | $41,618 | $16,913 | | **Distribution** | $10,065 | $1,629 | | **Total** | **$51,683** | **$18,542** | | Geographic Region (Six months ended June 30, 2022) | Revenues (in thousands) | | :--- | :--- | | **U.S.A and North America** | $28,562 | | **Israel** | $12,319 | | **Europe** | $5,149 | | **Latin America** | $3,526 | | **Asia** | $1,760 | | **Others** | $367 | | **Total** | **$51,683** | [Note 5: Financial Instruments](index=19&type=section&id=Note%205%3A%20Financial%20Instruments) As of June 30, 2022, derivative instruments with a **$437 thousand** fair value liability are Level 2, and contingent consideration with a **$23.1 million** liability is Level 3 in the fair value hierarchy | Financial Instrument (June 30, 2022) | Fair Value (in thousands) | Hierarchy Level | | :--- | :--- | :--- | | Derivatives instruments | ($437) | Level 2 | | Contingent consideration | ($23,121) | Level 3 | [Note 6: Subsequent events](index=19&type=section&id=Note%206%3A%20Subsequent%20events) The Beit Kama labor strike ended on July 15, 2022, with a new agreement, and a terminated distributor initiated a conciliation hearing on July 18, 2022, seeking damages, with unassessable prospects - The labor strike at the Beit Kama manufacturing plant ended following the signing of a new collective agreement on **July 15, 2022**[28](index=28&type=chunk)[38](index=38&type=chunk) - On **July 18, 2022**, an affiliate of a terminated distributor for Russia and Ukraine filed a request for a conciliation hearing in Geneva, seeking damages. The company cannot yet assess the potential liability and intends to defend itself vigorously[38](index=38&type=chunk)

Kamada Ltd. (NASDAQ:KMDA) Q1 2022 Earnings Conference Call May 17, 2022 8:30 AM ET Company Participants Bob Yedid - LifeSci Advisors Amir London - Chief Executive Officer Chaime Orlev - Chief Financial Officer Conference Call Participants Operator Greetings. Welcome to the Kamada Ltd. First Quarter 2022 Earnings Conference Call. [Operator Instructions] Please note, this conference is being recorded. I will now turn the conference over to your host, Bob Yedid of LifeSci Advisors. You may begin. Bob Yedid Tha ...